Advanced hepatocellular carcinoma (HCC) is a serious therapeutic challenge and targeted
therapies only provide a modest benefit in terms of overall survival. Novel approaches are …

Treatment options for patients with hepatocellular carcinoma are rapidly changing based on
positive results from phase 3 trials of targeted and immune-based therapies. More agents …

Heparan sulfate (HS) proteoglycans (PGs) are ubiquitously expressed on cell surfaces and
in the extracellular matrix of most animal tissues, having essential functions in development …

Purpose: The aim of our study is to elucidate whether T cells expressing GPC3-targeted
chimeric antigen receptor (CAR) can efficiently eliminate GPC3-positive HCC cells and their …

While calcium‐overload‐mediated therapy (COMT) is a promising but largely untapped
therapeutic strategy, combinatory therapy greatly boosts treatment outcomes with integrated …

Heparan sulfate (HS) are complex unbranched carbohydrate chains that are heavily
modified by sulfate and exist either conjugated to proteins or as free, unconjugated chains …

Hepatocellular carcinoma (HCC) is a cause of several deaths related to cancer worldwidely.
In early stage, curative treatments such as surgical resection, liver transplant and local …

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths and
the fifth most common cancer worldwide. Most of these patients are seen with advanced …

Background Glypican-3 (GPC3), a cell surface glycoprotein that is pathologically highly
expressed in hepatocellular carcinoma (HCC), is an attractive target for immunotherapies …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is
associated with a dismal median survival of 2–9 months. The fundamental limitations and …